The Drug Discovery World Podcast Drug Discovery World (DDW)

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 
The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so this round-up focuses on drug discovery in oncology.
You can to The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 
In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders and alcohol use disorder, and a significant acquisition for Novo Nordisk, as well as the discovery of a new way to target dormant cancer cells.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Flow cytometry for drug discovery research” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW.
They are called: Flow cytometry technologies and cancer associated fibroblasts and Leveraging flow cytometry in drug discovery.
In the first article, Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done.
In the second article, Dr Miguel A Tam, and Dr Kenta Yamamoto, BioLegend, examine the evolution, trends and best practices for smooth and efficient workflows for flow cytometry.
You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 
Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.   
In this episode, Megan Thomas is in conversation with Ahmed Mousa, CEO of Vicore Pharma. Vicore Pharma is exploring the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), and here Mousa provides DDW with an overview of the company’s unique approach, its challenges, its opportunities, and its context in the scientific community. 
You can listen here, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 
It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and the announcement that the FDA will delay approval of donanemab to hold a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.